Antioxidants could reduce chemo efficacy

6 July 2008

A new study published in the Journal of the National Cancer Institute has thrown into question the health benefits of taking antioxidants as an adjunct to chemotherapy. A team of US researchers reviewed findings from several trials and found that supplements such as beta carotene and vitamin E may actually reduce the effectiveness of cancer treatment.

According to the analysis, led by Brian Lawenda of the Naval Medical Center in San Diego, USA, the use of supplemental antioxidants during chemotherapy and radiation therapy should be discouraged because of the possibility of tumor protection and reduced survival. Some data indicate they may protect tumor cells as well as healthy cells from oxidative damage generated by treatments. However, other data suggest that antioxidants can protect normal tissues from chemotherapy- or radiation-induced damage without decreasing tumor control, he wrote.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight